Last reviewed · How we verify
Quadrivalent Influenza Virus Vaccine
Quadrivalent Influenza Virus Vaccine, marketed by Sanofi Pasteur, holds a significant position in the influenza vaccine market. A key strength is the protection it offers against four strains of the influenza virus, enhancing its efficacy and appeal to healthcare providers. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic manufacturers.
At a glance
| Generic name | Quadrivalent Influenza Virus Vaccine |
|---|---|
| Also known as | Fluzone Quadrivalent |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Opioid, HIV and Immune System (PHASE4)
- BPL-1357 Against H1N1 Influenza Virus Challenge (PHASE2)
- Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants (PHASE3)
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza (PHASE1)
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age (PHASE3)
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: